Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced this week that Steven C. Quay, M.D., Ph.D., Atossa’s President, and CEO, provided an update on the Company’s clinical programs at the Precision: Breast Cancer World R&D Summit.
The Precision Breast Cancer World R&D Summit is an exclusive, annual biopharma summit providing insights into the research and development of cutting-edge treatments for Breast Cancer and a networking forum for precision medicine leaders in this space. From therapeutics to diagnostics, the summit brings together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. The discussion and presentations are based around the latest trends in personalized medicine, using case studies covering early discovery to clinical development.
Dr. Quay’s presentation titled, “A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy,” included the following updates:
Ongoing Phase 2 Study: Dosing has been completed in Atossa’s Phase 2 clinical study of topical Endoxifen to reduce mammographic breast density. Analysis of the results is underway and expected to be announced this quarter.
Expanded Access Program: The first safety endpoint has been successfully achieved in the FDA-approved expanded access program using Atossa’s proprietary oral Endoxifen to treat a single patient following breast cancer surgery. The patient in this study continues to experience a few side effects from Endoxifen.
Intraductal Immunotherapy Program: Atossa recently completed the first phase of a preclinical study using Atossa’s proprietary intraductal delivery technology. Imaging of the mammary ducts of mice showed that dye was successfully dispersed throughout the mammary duct system. Based on these encouraging results, Atossa is advancing to the next preclinical phase which involves the intraductal administration of immune modulating formulations. This preclinical work will form the basis for advancing the intraductal delivery program into humans and to ultimately deliver immunotherapy to treat breast cancer using Atossa’s proprietary intraductal delivery technology.